1. Home
  2. AWX vs BLRX Comparison

AWX vs BLRX Comparison

Compare AWX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AWX

Avalon Holdings Corporation

N/A

Current Price

$2.67

Market Cap

10.5M

Sector

Utilities

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.98

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AWX
BLRX
Founded
1998
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
12.6M
IPO Year
1998
2011

Fundamental Metrics

Financial Performance
Metric
AWX
BLRX
Price
$2.67
$2.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
14.5K
23.3K
Earning Date
11-07-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$79,712,000.00
$12,735,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$59.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$2.30
52 Week High
$5.43
$7.77

Technical Indicators

Market Signals
Indicator
AWX
BLRX
Relative Strength Index (RSI) 56.82 42.91
Support Level $2.58 $2.82
Resistance Level $2.80 $2.99
Average True Range (ATR) 0.11 0.18
MACD 0.01 0.02
Stochastic Oscillator 76.06 46.66

Price Performance

Historical Comparison
AWX
BLRX

About AWX Avalon Holdings Corporation

Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: